Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group.

di Bartolomeo M, Bajetta E, Buzzoni R, Mariani L, Carnaghi C, Somma L, Zilembo N, di Leo A

Cancer1 Jan 1996Cited by 182 (Europe PMC)

PMID8625251DOI10.1002/(sici)1097-0142(19960115)77:2<402::aid-cncr25>3.0.co;2-4PepBankPUB-08625251

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanNon-randomized trialEfficacy outcome
In metastatic neuroendocrine tumors treated with octreotide, an effect on tumor growth occurred in two patients with carcinoids, with a partial response rate of 3%.
In plain wordsIn metastatic neuroendocrine tumors treated with octreotide, two patients showed tumor response.
Peptide
Octreotide
Outcome
Not applicableTumor response
Study
n = 58
Outcome group
Tumor growth · Cancer
Studied dose
500 or 1000 micrograms 3 times a day · subcutaneous · Median 5 months, range 2-31 monthsAs given in this study (human).
Measurements
Patients with an effect on tumor growth
2 patients
carcinoid patients
Partial response
3%
all treated patients
Source sentences
Summary
There was an effect on tumor growth in two patients with carcinoids.
2 context sentences(design, population, supporting numbers)
Summary · context
In terms of tumor regression, octreotide is disappointing (partial response: 3%); symptomatic response and biochemical control are satisfactory.
Summary · context
Fifty-eight patients were treated subcutaneously with 2 sequential doses of the drug (Sandostatina, Sandoz, Inc., S.b.A. Pharmaceuticals, Basel, Switzerland). The first 23 patients received 500 micrograms 3 times a day and the remaining 35 patients received 1000 micrograms 3 times a day. The treatme…
Report a problemFND-0862525101
02HumanNon-randomized trialEfficacy outcome
In metastatic neuroendocrine tumors treated with octreotide, disease stabilized in twenty-seven patients for at least 6 months, ranging from 6-32+ months.
In plain wordsIn metastatic neuroendocrine tumors treated with octreotide, disease stabilized in twenty-seven patients for at least 6 months.
Peptide
Octreotide
Outcome
Not applicableDisease stabilization
Study
n = 58
Outcome group
Tumor growth · Cancer
Studied dose
500 or 1000 micrograms 3 times a day · subcutaneous · Median 5 months, range 2-31 monthsAs given in this study (human).
Measurements
Patients with disease stabilized for at least 6 months
27 patients
58 treated patients
Duration of disease stabilization
6 to 32 months
range 6 to 32+ months
Source sentences
Summary
In twenty-seven patients, the disease stabilized for at least 6 months (range, 6-32+).
1 context sentence(design, population, supporting numbers)
Summary · context
Fifty-eight patients were treated subcutaneously with 2 sequential doses of the drug (Sandostatina, Sandoz, Inc., S.b.A. Pharmaceuticals, Basel, Switzerland). The first 23 patients received 500 micrograms 3 times a day and the remaining 35 patients received 1000 micrograms 3 times a day. The treatme…
Report a problemFND-0862525104
03HumanNon-randomized trialEfficacy outcome
In metastatic neuroendocrine tumors treated with octreotide, median survival was 22 months, with a range of 1-32+ months.
In plain wordsIn metastatic neuroendocrine tumors treated with octreotide, median survival was 22 months.
Peptide
Octreotide
Outcome
Not applicableSurvival
Study
n = 58
Outcome group
Mortality · Cancer
Studied dose
500 or 1000 micrograms 3 times a day · subcutaneous · Median 5 months, range 2-31 monthsAs given in this study (human).
Measurements
Median survival
22 months
all patients
Survival range
1 to 32 months
all patients; upper bound 32+ months
Source sentences
Summary
The median survival time for all patients was 22 months (range, 1-32+).
1 context sentence(design, population, supporting numbers)
Summary · context
Fifty-eight patients were treated subcutaneously with 2 sequential doses of the drug (Sandostatina, Sandoz, Inc., S.b.A. Pharmaceuticals, Basel, Switzerland). The first 23 patients received 500 micrograms 3 times a day and the remaining 35 patients received 1000 micrograms 3 times a day. The treatme…
Report a problemFND-0862525105
04HumanNon-randomized trialEfficacy outcome
In metastatic neuroendocrine tumors treated with octreotide, symptomatic control occurred in 73% of patients.
In plain wordsIn metastatic neuroendocrine tumors treated with octreotide, symptoms were controlled in 73% of patients.
Peptide
Octreotide
Outcome
Not applicableSymptomatic control
Study
n: not reported in source
Outcome group
Carcinoid Symptoms · Cancer
Studied dose
500 or 1000 micrograms 3 times a day · subcutaneous · Median 5 months, range 2-31 monthsAs given in this study (human).
Measurements
Symptomatic control
73 % of patients
treated patients
Source sentences
Summary
Symptomatic control was achieved in 73% of patients and a biochemical response in 77% of patients.
1 context sentence(design, population, supporting numbers)
Summary · context
Fifty-eight patients were treated subcutaneously with 2 sequential doses of the drug (Sandostatina, Sandoz, Inc., S.b.A. Pharmaceuticals, Basel, Switzerland). The first 23 patients received 500 micrograms 3 times a day and the remaining 35 patients received 1000 micrograms 3 times a day. The treatme…
Report a problemFND-0862525102
05HumanNon-randomized trialEfficacy outcome
In metastatic neuroendocrine tumors treated with octreotide, biochemical response occurred in 77% of patients.
In plain wordsIn metastatic neuroendocrine tumors treated with octreotide, 77% showed a biochemical response.
Peptide
Octreotide
Outcome
Not applicableBiochemical response
Study
n: not reported in source
Outcome group
Cancer biomarkers and prognosis · Cancer
Studied dose
500 or 1000 micrograms 3 times a day · subcutaneous · Median 5 months, range 2-31 monthsAs given in this study (human).
Measurements
Biochemical response
77 % of patients
treated patients
Source sentences
Summary
Symptomatic control was achieved in 73% of patients and a biochemical response in 77% of patients.
1 context sentence(design, population, supporting numbers)
Summary · context
Fifty-eight patients were treated subcutaneously with 2 sequential doses of the drug (Sandostatina, Sandoz, Inc., S.b.A. Pharmaceuticals, Basel, Switzerland). The first 23 patients received 500 micrograms 3 times a day and the remaining 35 patients received 1000 micrograms 3 times a day. The treatme…
Report a problemFND-0862525103

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.